Ionis Partner Biogen Unveils Positive Phase 2 CELIA Data for Diranersen at AAIC
Ionis and Biogen Report Positive Phase 2 Results for Diranersen in Early Alzheimer’s Disease, Supporting Advancement to Phase 3 Ionis Pharmaceuticals, Inc. has announced that its long-standing collaboration partner, Biogen,…
BioXcellerator to Discuss Regenerative Medicine for Veterans at Congressional Care Forum
BioXcellerator Joins Congressional Veterans Care Forum to Advance Dialogue on Evidence-Based Regenerative Medicine BioXcellerator, a global provider of evidence-based regenerative medicine therapies, has announced that its Co-Founder and Chief Executive…
Hologic Expands CE-IVDR Approval for Aptima® HPV Test to Support Self-Collected Samples
Hologic Expands CE-IVDR Approval for Aptima HPV Assay to Support Self-Collected Cervical Cancer Screening Samples Hologic, Inc. has announced that its Aptima® HPV Assay has received an expanded CE-IVDR marking…
OmniAb Appoints Amechi Nwachuku as Chief Operating Officer
OmniAb Appoints Amechi Nwachuku as Chief Operating Officer to Accelerate Growth of xPloration® Single B-Cell Screening Platform OmniAb, Inc., a biotechnology company recognized for its advanced antibody discovery technologies that…
Charles River Partners with Arovella Therapeutics on NGS Services
Charles River Laboratories Partners with Arovella Therapeutics to Advance GMP Next-Generation Sequencing for CAR-iNKT Cell Therapy Development Charles River Laboratories International, Inc. has announced a strategic collaboration with Arovella Therapeutics…
CEL-SCI to Launch Phase 3 Confirmatory Trial for Multikine®
CEL-SCI Launches Global Confirmatory Registration Study of Multikine® for Newly Diagnosed Head and Neck Cancer CEL-SCI Corporation has announced the initiation of its global Confirmatory Registration Study evaluating Multikine® (Leukocyte…
Lineage Updates COR1 Cell Therapy Program for Corneal Disease
Lineage Cell Therapeutics Advances COR1 Program to Develop Off-the-Shelf Cell Therapy for Corneal Endothelial Disease Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf cell therapies…
Cognito Therapeutics Presents New Biomarker Data at AAIC 2026
Cognito Therapeutics Presents New Biomarker Findings Highlighting Potential Mechanism of Spectris™ Neuromodulation for Alzheimer’s Disease Cognito Therapeutics, a clinical-stage neurotechnology company focused on developing innovative therapies for neurodegenerative diseases, has…
Universal Brain Secures FDA 510(k) Clearance for Psychiatry Platform
Universal Brain Receives FDA 510(k) Clearance for UB ERP System, Advancing Objective Brain Function Assessment in Mental Health Care Universal Brain, a neurotechnology company focused on developing objective tools to…
HistoSonics Secures CE Mark for Edison® Histotripsy Platform
HistoSonics Secures CE Mark Approval for Edison® Histotripsy System, Expanding Non-Invasive Liver Tumor Treatment Across Europe HistoSonics has achieved a significant regulatory milestone with the receipt of CE Mark approval…
Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer
Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer to Advance RNA Medicine Pipeline and Genetic Disease Research Stoke Therapeutics, Inc. has announced the appointment of Thomas McCauley, Ph.D., as…
Alkermes Reports Long-Term Alixorexton Data in Narcolepsy
Alkermes Reports Sustained Long-Term Benefits of Alixorexton in Narcolepsy Types 1 and 2 Alkermes plc has announced encouraging interim results from the ongoing long-term extension (LTE) study evaluating alixorexton, its…